Drug Profile


Alternative Names: PCA 4248

Latest Information Update: 23 Nov 2006

Price : $50

At a glance

  • Originator Alter
  • Class Antiasthmatics; Antithrombotics
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Cerebral ischaemia; Heart transplant rejection; Inflammatory bowel diseases; Septic shock

Most Recent Events

  • 06 Nov 1996 Investigation in Heart transplant rejection in Spain (Unknown route)
  • 06 Nov 1996 Investigation in Inflammatory bowel disease in Spain (Unknown route)
  • 06 Nov 1996 Investigation in Cerebral ischaemia in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top